Overview

Price chart · mood · technical indicators

ACAD

ACADIA Pharmaceuticals Incstock Healthcare

Biotechnology

$21.430.42%Current Market Mood:Bearish

Market Mood

Price Range (1Y)

$19.69$28.35

Current: $21.43

Idea: SMA

1Y Return

+65.5%

Sharpe 3Y

0.73

Market Comparison

vs Healthcare Sector & Biotechnology Industry

ACAD

+0.42%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio9.70Forward 60.61

EPS (TTM)$2.21-81.8% YoY

Profit margin34.3%HEALTHCARE

Market cap$3.67BMid cap

Wall Street coverage

$31.65median target· current $15.32 (+106.6%)21 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 60.61
PEG ratio: 50.86
P/B: 2.87
P/S (TTM): 3.35
EV/EBITDA: 29.96

Profitability & growth

ROE (TTM): 37.3%
Operating margin: -1.7%
Revenue growth YoY: 9.7%
Dividend yield: —
Beta: 0.86

Last earnings

May 6, 2026 · Estimate $0.08 · Reported $0.02

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About ACADIA Pharmaceuticals Inc

Company profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 12830 EL CAMINO REAL, SAN DIEGO, CA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$3.67B

Shares outstanding$171.2M

52W high$28.35

52W low$19.69

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

ACAD

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Baker funds tied to ACAD (ACAD) report RSU and stock option grants

Technical Reactions to ACAD Trends in Macro Strategies

ACADIA (NASDAQ: ACAD) director granted RSUs and stock options

ACAD Financials: Revenue Breakdown, Margins & Competitor Comparison

ACADIA (NASDAQ: ACAD) director granted RSUs, options and exercises into shares

ACADIA Pharmaceuticals (ACAD) director receives new RSUs and stock option grant

ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards

Acadia Shareholders Approve Directors, Executive Pay and Equity Plan

Acadia Shareholders Approve Directors, Executive Pay and Equity Plan

A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $38

Acadia Pharmaceuticals (NASDAQ: ACAD) investors approve 5.2M-share boost to 2024 equity plan

Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock

Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)

[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity

Acadia principal accounting officer Kihara sells $114,393 stock

ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms

Form 144 lists 3,857 performance shares and ESPP lots for ACAD (NASDAQ: ACAD)

Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices

Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts

Trading the Move, Not the Narrative: (ACAD) Edition

About ACADIA Pharmaceuticals Inc

Classification

Company profile

ACAD

Market Comparison

ACAD Market Analysis

Overview

ACAD

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Baker funds tied to ACAD (ACAD) report RSU and stock option grants

Technical Reactions to ACAD Trends in Macro Strategies

ACADIA (NASDAQ: ACAD) director granted RSUs and stock options

ACAD Financials: Revenue Breakdown, Margins & Competitor Comparison

ACADIA (NASDAQ: ACAD) director granted RSUs, options and exercises into shares

ACADIA Pharmaceuticals (ACAD) director receives new RSUs and stock option grant

ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards

Acadia Shareholders Approve Directors, Executive Pay and Equity Plan

Acadia Shareholders Approve Directors, Executive Pay and Equity Plan

A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $38

Acadia Pharmaceuticals (NASDAQ: ACAD) investors approve 5.2M-share boost to 2024 equity plan

Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock

Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)

[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity

Acadia principal accounting officer Kihara sells $114,393 stock

ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms

Form 144 lists 3,857 performance shares and ESPP lots for ACAD (NASDAQ: ACAD)

Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices

Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts

Trading the Move, Not the Narrative: (ACAD) Edition

About ACADIA Pharmaceuticals Inc

Classification

Company profile

ACAD

Market Comparison